Table 2 Patients’ clinical outcome parameters.
From: Clinical features of BK-polyomavirus and cytomegalovirus co-infection after kidney transplantation
Variable | No viremia (n = 380) | CMV DNAemia (n = 182) | BKPyV DNAemia (n = 102) | CMV and BKPyV DNAemia (n = 59) | p value |
|---|---|---|---|---|---|
Time until viremia, median (months), 1st, 3rd quartile | – | 7.7 (3.5,17.4) | 4.0 (2.0,11.8) | 3.6 (2.2,6.0) | |
DGF (n) | 80 (21.1%) | 58 (31.9%) | 23 (22.5%) | 15 (25.4%) | 0.049b |
eGFR at year 1, mean ± SD (ml/min/1.73 m2) | 58.4 ± 19.3 | 52.4 ± 19.6 | 57.6 ± 24.2 | 40.2 ± 11.1 | 0.001a |
eGFR at year 3, mean ± SD (ml/min/1.73 m2) | 57.6 ± 19.0 | 51.9 ± 20.8 | 58.2 ± 27.2 | 40.6 ± 15.8 | 0.021a |
eGFR at year 5, mean ± SD (ml/min/1.73 m2) | 54.4 ± 19.7 | 47.8 ± 20.8 | 52.0 ± 28.8 | 42.9 ± 12.2 | 0.004a |
UPCR at year 1, mean ± SD (mg/g crea) | 225 ± 200 | 155 ± 130 | 203 ± 318 | 279 ± 96 | 0.003a |
UPCR at year 5, mean ± SD (mg/g crea) | 455 ± 587 | 310 ± 320 | 245 ± 432 | 308 ± 361 | 0.304a |
Overall graft survival (mean, months) (95% CI) | 124.1 (119.0–129.2) | 114.8 (108.2–121.4) | 122.4 (113.4–131.5) | 109.0 (95.4–122.8) | 0.834c |
NODAT* (n) | 55 (14.5%) | 38 (20.9%) | 18 (17.6%) | 6 (10.2%) | 0.109b |
Pre-existent diabetes (n) | 44 (11.6%) | 27 (14.8%) | 9 (8.8%) | 12 (20.4%) | 0.134 |
Highest CMV load, median (IU/ml), 1st, 3rd quartile | – | 1,100 (250,8163) | – | 36,525 (8058, 428,323) | 0.687d |
Highest BKPyV load, median (IU/ml), 1st–3rd quartile | – | – | 8565 (3,289,43,650) | 75,885 (26,471, 98,900) | 0.898d |
Rejection yes (n) | 126 (33.2%) | 75 (41.2%) | 45 (44.1%) | 35 (59.3%) | 0.001b |
Antibody-mediated rejection | 33 (8.7%) | 3 (2.9%) | 15 (10.4%) | 6 (10.2%) | |
T-cellular rejection | 35 (9.2%) | 8 (7.8%) | 17 (9.3%) | 5 (8.5%) | |
Combined rejection | 19 (5.0%) | 8 (7.8%) | 20 (11.0%) | 8 (13.6%) | |
T-cell-borderline rejection | 39 (10.3%) | 25 (24.5%) | 20 (11.0%) | 16 (27.1%) |
